XML 48 R37.htm IDEA: XBRL DOCUMENT v3.10.0.1
Business Combination - Additional Information (Detail)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 13, 2018
May 04, 2017
USD ($)
shares
Sep. 30, 2018
USD ($)
Mar. 31, 2018
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2017
USD ($)
Dec. 31, 2017
USD ($)
Business Acquisition [Line Items]                
Reverse stock split of common stock 0.03              
Share exchange ratio           1-for-1 basis    
Debt converted in to equity   10,558            
Conversion of stock | shares   229,450            
Operating loss carryforwards     $ 3,300,000     $ 3,300,000    
Transaction costs   $ 2,183,671            
Increase in goodwill from recorded adjustments           490,676    
Discount rate   23.00%            
Goodwill       $ 0        
Goodwill impairment charge       $ 490,676 $ 26,600,000 490,676 $ 26,600,000  
Revenue     2,634,393   4,591,940 7,742,514 7,929,484  
Net Income     (2,351,149)   $ (29,905,237) (14,663,529) $ (37,594,401)  
Change in fair value of derivatives           90,191    
Reversal of interest expense           722,029    
Restricted Stock Units (RSUs) [Member]                
Business Acquisition [Line Items]                
Conversion of stock | shares   1,325            
Series B Preferred Stock [Member]                
Business Acquisition [Line Items]                
Conversion of preferred stock   $ 19,976            
Common Stock Class A [Member]                
Business Acquisition [Line Items]                
Common stock issued | shares   229,450            
United States [Member]                
Business Acquisition [Line Items]                
Operating loss carryforwards     $ 965,583     $ 965,583    
Operating loss carryforwards, expiration date           Jan. 01, 2023    
Reversal of Acquisition Related Costs [Member]                
Business Acquisition [Line Items]                
Nonrecurring pro forma adjustments           $ 2,341,279    
Common Stock Warrants [Member]                
Business Acquisition [Line Items]                
Conversion of stock | shares   22,024            
PharmAthene [Member]                
Business Acquisition [Line Items]                
Reverse stock split of common stock   0.0249702            
Equity interests acquired   58.20%            
Total fair value of consideration   $ 44,742,737            
Outstanding unvested options | shares   252            
Stock options estimated fair value   $ 15,173            
Increase tax refund receivable due to adjustments to the allocation of the purchase consideration               $ 44,700
Reduce deferred tax liability due to adjustments to the allocation of the purchase consideration               4,535
Increase in goodwill due to adjustments to the allocation of the purchase consideration               $ 49,235
Change in tax rate           35.00%   34.00%
Goodwill   $ 16,064,498            
Revenue           $ 1,743,619    
Net Income           56,952    
Nonrecurring pro forma adjustments           (39,277,568)    
PharmAthene [Member] | Stock Compensation Expense [Member]                
Business Acquisition [Line Items]                
Nonrecurring pro forma adjustments           $ 66,367